Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Acta Oncol ; 58(10): 1352-1357, 2019 Oct.
Article in English | MEDLINE | ID: mdl-31241387

ABSTRACT

Purpose: A 1.5 T MR Linac (MRL) has recently become available. MRL treatment workflows (WF) include online plan adaptation based on daily MR images (MRI). This study reports initial clinical experiences after five months of use in terms of patient compliance, cases, WF timings, and dosimetric accuracy. Method and materials: Two different WF were used dependent on the clinical situation of the day; Adapt To Position WF (ATP) where the reference plan position is adjusted rigidly to match the position of the targets and the OARs, and Adapt To Shape WF (ATS), where a new plan is created to match the anatomy of the day, using deformable image registration. Both WFs included three 3D MRI scans for plan adaptation, verification before beam on, and validation during IMRT delivery. Patient compliance and WF timings were recorded. Accuracy in dose delivery was assessed using a cylindrical diode phantom. Results: Nineteen patients have completed their treatment receiving a total of 176 fractions. Cases vary from prostate treatments (60Gy/20F) to SBRT treatments of lymph nodes (45 Gy/3F) and castration by ovarian irradiation (15 Gy/3F). The median session time (patient in to patient out) for 127 ATPs was 26 (21-78) min, four fractions lasted more than 45 min due to additional plan adaptation. For the 49 ATSs a median time of 12 (1-24) min was used for contouring resulting in a total median session time of 42 (29-91) min. Three SBRT fractions lasted more than an hour. The time on the MRL couch was well tolerated by the patients. The median gamma pass rate (2 mm,2% global max) for the adapted plans was 99.2 (93.4-100)%, showing good agreement between planned and delivered dose. Conclusion: MRL treatments, including daily MRIs, plan adaptation, and accurate dose delivery, are possible within a clinically acceptable timeframe and well tolerated by the patients.


Subject(s)
Magnetic Resonance Imaging/methods , Particle Accelerators , Radiosurgery/methods , Radiotherapy Planning, Computer-Assisted/methods , Adult , Aged , Aged, 80 and over , Castration/instrumentation , Castration/methods , Cohort Studies , Feasibility Studies , Female , Humans , Lymph Nodes/diagnostic imaging , Lymph Nodes/radiation effects , Lymphatic Metastasis/diagnostic imaging , Lymphatic Metastasis/radiotherapy , Magnetic Resonance Imaging/instrumentation , Male , Middle Aged , Ovary/diagnostic imaging , Ovary/radiation effects , Patient Compliance/statistics & numerical data , Phantoms, Imaging , Prostate/diagnostic imaging , Prostate/radiation effects , Prostatic Neoplasms/diagnostic imaging , Prostatic Neoplasms/radiotherapy , Radiometry , Radiosurgery/instrumentation , Radiotherapy Dosage , Radiotherapy Planning, Computer-Assisted/instrumentation , Time Factors , Treatment Outcome
2.
Article in English | MEDLINE | ID: mdl-32095592

ABSTRACT

BACKGROUND AND PURPOSE: Overall treatment time (OTT) is essential for local tumour control and survival in radiotherapy of head and neck cancer (HNC). National radiotherapy guidelines of the Danish Head and Neck Cancer Group (DAHANCA) recommend a maximum OTT of 41 days for moderately accelerated radiation treatment (6 fractions/week) and 48 days for conventional treatment (5 fractions/week). The purpose of this study was to evaluate the effect of surveillance of the radiotherapy course length and treatment gaps in HNC patients to reduce OTT. METHODS: The study included 2011 patients with HNC undergoing radical radiation treatment with 66-68 Gy in 33-34 fractions in 2003-2017 at Odense University Hospital. In February 2016, a systematic weekly review by two radiation therapists of all planned treatment courses was introduced to check OTT of individual patients to portend likely breaks or treatment prolongations. Schedules that violated the OTT guidelines were conferred with the responsible radiation oncologist, and treatment rescheduled by treating twice daily to catch up with a delay. RESULTS: The mean length of accelerated treatment courses was reduced from a maximum of 40.9 days in 2007 to 38.3 days in 2017 and from 50.3 days to 45.9 days for conventional courses. The percentage of individual treatment courses that violated the recommended OTT was reduced to 3% of the accelerated treatments and 13% for the conventional treatments. CONCLUSION: Continuous surveillance of treatment schedules of HNC patients by a brief weekly survey reduced treatment course duration to an extent that was radiobiologically and clinically meaningful.

SELECTION OF CITATIONS
SEARCH DETAIL